Front Cover --;Contents --;Chapter 1 Introduction: Cancer vaccines-mechanisms and a clinical overview --;Chapter 2 Revisiting the paradigm on the putative need for antigen-specific responses in cancer --;Chapter 3 Development of novel immune interventions for genito-urinary cancers --;Chapter 4 Autologous cellular immunotherapy in late-stage prostate cancer: The development history of Sipuleucel-T (PROVENGE®) --;Chapter 5 Design, development, and translation of poxvirus-based vaccines for cancer --;Chapter 6 Of mice and men (and dogs!): The fi rst approved cancer therapy vaccine --;Chapter 7 Recombinant protein vaccination for antigen-specifi c cancer immunotherapy --;Chapter 8 Antigen-targeted, synthetic vaccines for metastatic cancer --;Chapter 9 Clinical perspectives in cancer vaccines for hematological diseases --;Chapter 10 Epitope-based vaccines for cancer --;Chapter 11 Emerging clinical trial design concepts for therapeutic cancer vaccines --;Chapter 12 T-cell immune monitoring assays to guide the development of new cancer vaccines --;Chapter 13 A biomarker-based, systems biology approach guiding the development of active immunotherapies and immune monitoring --;Chapter 14 Targeting regulatory T cells and other strategies to enable cancer vaccines --;Chapter 15 Molecular targeting of cancer stem cells --;Chapter 16 RNA in cancer vaccine therapy --;Chapter 17 Induction of innate immunity by nucleic acids: A potential adjuvant for cancer vaccines? --;Chapter 18 Passive immunotherapy by T cell-engaging bispecifi c antibodies --;Chapter 19 Antibodies to peptide-HLA complexes have potential application for cancer diagnosis and therapy --;Index --;Back Cover.